Business Context and Reporting Period
This Form 6-K filing by Genmab A/S covers the month of June 2025, with the report dated June 10, 2025. The filing serves as a report of a foreign private issuer pursuant to Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934. The primary purpose of this specific filing is to disclose details regarding transactions executed under the company's share buy-back program.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This document is a regulatory disclosure of corporate actions rather than a financial results report.
Material Changes
The material change disclosed in this filing relates to the execution of the company's share buy-back program. Specifically, the filing includes an appendix detailing the specification for buy-back transactions conducted between June 2 and June 6, 2025.
Guidance, Outlook, and Risks
The filing does not contain updated financial guidance, management commentary on future outlook, or a discussion of new risks and contingencies. The document is limited to the announcement of the share buy-back transactions and incorporates by reference into existing registration statements on Form S-8.
Key Facts for Investor Verification
- Verify the specific number of shares repurchased and the average price per share during the June 2–6, 2025 period via the referenced Exhibit 99.1(a).
- Confirm the remaining authorization limit for the share buy-back program following these transactions.
- Note that this filing does not include quarterly or annual financial performance data; investors should refer to the most recent Form 20-F or interim reports for financial metrics.